Americold Initiated Neutral by Piper Sandler Piper Sandler initiated Americold (COLD) at Neutral on Apr 1, 2026 (Investing.com), flagging transition‑related execution risk and the need to monitor occupancy, margins, and leverage.

Americold Initiated Neutral by Piper Sandler: Piper Sandler initiated Americold (COLD) at Neutral on Apr 1, 2026 (Investing.com), flagging transition‑related execution risk and the need to monitor occupancy, margins, and… 👈 Read full analysis #Investing #Finance #StockMarket #Americold #PiperSandler

Cisco Neutral Rating Held by Piper Sandler on Mar 30 Piper Sandler kept a Neutral on Cisco on Mar 30, 2026, citing a security-driven revenue timing drag; watch ARR and subscription renewals as the key de-risk signals.

Cisco Neutral Rating Held by Piper Sandler on Mar 30: Piper Sandler kept a Neutral on Cisco on Mar 30, 2026, citing a security-driven revenue timing drag; watch ARR and subscription renewals as the key de-risk signals. 👈 Read full analysis #Cisco #PiperSandler #NeutralRating #StockMarket #Investment

JPMorgan Price Target Cut by Piper Sandler Piper Sandler cut JPMorgan’s 12‑month price target to $195 on Mar 30, 2026, trimming 2026 EPS estimates by ~6% and prompting a ~1.5% share decline that day.

JPMorgan Price Target Cut by Piper Sandler: Piper Sandler cut JPMorgan’s 12‑month price target to $195 on Mar 30, 2026, trimming 2026 EPS estimates by ~6% and prompting a ~1.5% share decline that day. 👈 Read full analysis #JPMorgan #PriceTarget #PiperSandler #FinanceNews #StockMarket

Relmada Draws Bullish Take from Piper Sandler Piper Sandler issued a bullish note on Relmada on Mar 24, 2026 (Seeking Alpha). Institutional investors should weigh this signal against upcoming trial readouts and cash runway.

Relmada Draws Bullish Take from Piper Sandler: Piper Sandler issued a bullish note on Relmada on Mar 24, 2026 (Seeking Alpha). Institutional investors should weigh this signal against upcoming trial… 👈 Read full analysis #Relmada #PiperSandler #BullishMarket #InvestmentInsights #PharmaStocks

#trends today for 'house districts' 'texas schools' & 'piper sandler'

Click/Tap below:

www.newsmason.com?query=%22hou...

www.newsmason.com?query=%22tex...

www.newsmason.com?query=%22pip...

#housedistricts #texasschools #pipersandler

Piper hikes price target on Nvidia stock, expects another earnings beat Investing.com -- Piper Sandler hiked its price target on Nvidia (NASDAQ:NVDA) to $225 from $180 ahead of the tech giant’s earnings report due later this month, citing expectations for another solid print and strong demand trends into the second half of the year. The brokerage said it sees “upside to numbers for both the July and October quarters,” supported by robust U.S. hyperscaler spending and the inclusion of China revenues. Piper also said that “guidance and commentary around China revenue for the October quarter” will be a key focus of the earnings call, as orders from Chinese customers could balloon given perceived urgency to secure supply. For the July quarter, Piper is modeling revenue of about $45.1 billion, roughly in line with Nvidia’s original guidance and just below Street estimates of $45.7 billion. Analyst Harsh V. Kumar said there is potential for “slight upside” given Nvidia’s history of modest beats and easing supply constraints in its data center business. China sales are expected to begin contributing meaningfully in the October quarter, with Piper estimating $5.5 billion to $6.5 billion in revenue from that market during the period. Kumar pointed to the recent “15% cut of revenue” deal with the Trump administration, which allows resumed shipments of advanced AI chips to China, as a catalyst for the October and subsequent quarters. He added that this agreement could weigh on gross margins for the Chinese business by roughly 15%, bringing them to about 60%, even though the H20 chip carries margins “at par or slightly higher” than Nvidia’s low-70% overall rate. He expects China demand to ramp quickly, reaching around $10 billion by the January quarter and potentially $50 billion annually by fiscal 2027 under current terms. "China demand in our view could amount to ~$6B in sales for the October quarter and further ramp from there at a ~12-15% growth rate moving forward in a normal quarter," Kumar said. The analyst also highlighted “elevated and resilient” hyperscale capital expenditure (capex) in the U.S., with major cloud providers signaling increased investment in compute capacity over the next few years. While Nvidia remains in a “demand greater than supply situation,” Kumar believes the company is well positioned to meet strong order flow from both U.S. and Chinese customers. He also argued that gross margins in the October and January quarters could be temporarily boosted by the sale of previously written-off H20 chip inventory. At $183.16, Nvidia trades at 29.8 times Piper’s fiscal 2027 non-GAAP EPS estimate of $6.15, above the peer average of 26.9 times. The new target implies a ~37x multiple, which the broker said reflects “peer multiple expansion.”

Click Subscribe #Nvidia #EarningsReport #StockMarket #Investing #PiperSandler

Piper Sandler starts AbbVie as it sees growth shielded from drug patent losses Investing.com -- Piper Sandler began coverage of AbbVie (NYSE:ABBV) with an Overweight rating and a $231 price target, saying the U.S. drugmaker’s revenue is better protected from major patent expirations than many peers. “AbbVie is in the enviable position of not having to countenance major loss of exclusivity (LOE) exposure through the end of the decade,” said analysts at Piper Sandler. The brokerage said AbbVie faces no significant loss of exclusivity until the end of the decade, with its next major hit expected from psychiatric drug Vraylar in 2030, which should make up only about 6% of 2025 sales. Strong growth prospects for immunology drugs Skyrizi and Rinvoq, particularly in inflammatory bowel disease, along with expanding oncology sales and steady Botox demand, should support revenue and profit growth, the note said. Piper Sandler said patents on Rinvoq could run until 2038 and AbbVie is pursuing additional protections for Skyrizi, while most other key products face limited generic threats before the mid-2030s. “A good bit of the heavy lifting, growth-wise, will admittedly come from therapeutic indications for Botox,” analysts added. “We envision a return to growth for the aesthetic neuromodulator business, in part a function of the depth and breadth of consumer interest, and in part a function of new offerings” The firm also pointed to AbbVie’s growing oncology portfolio, including two commercial antibody-drug conjugates and more in development, and potential for renewed growth in the aesthetic Botox market aided by new products. Before you buy stock in ABBV, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is ABBV one of them?

Click Subscribe #AbbVie #PiperSandler #PharmaNews #StockMarket #DrugPatents

Down More Than 30%: Piper Sandler Says These 2 Beaten-Down Stocks Could Stage a Comeback - Yahoo Finance Down More Than 30%: Piper Sandler Says These 2 Beaten-Down Stocks Could Stage a Comeback  Yahoo Finance

Click Subscribe #StockMarket #Investing #FinanceNews #ComebackStocks #PiperSandler

Piper Sandler gets bullish on Monster Beverage, sees sustainable growth ahead Investing.com -- Piper Sandler upgraded Monster Beverage (NASDAQ:MNST) to Overweight, raising its price target from $54 to $74 in a note Friday after what it calls “better visibility on sustainable top-line and margin momentum.” The firm said it had been “overly careful to ensure that the energy category’s inexplicable 2024 funk was in the rear-view,” but now sees “better momentum… clearly in hand.” Monster’s Q2 2025 revenue growth of 9.4% beat Piper Sandler’s estimates by roughly 2.5 percentage points, with U.S. sales growth returning to the low teens and July global shipments up more than 20%. The firm added that international expansion, now 41% of sales, is a drag on mix given lower margins, but Q2 2025 gross margin still came in at 55.7%, 120 basis points above expectations. Piper Sandler expects a “manageable” $23–$24 million tariff headwind in the second half, projecting a 55.0% margin in Q3, up 180 basis points year-over-year. July’s momentum was seen as especially strong, with Monster posting 24.3% global sales growth (+22.8% ex-FX) and U.S.-measured retail sales in its Monster Energy Drink segment rising 11.6% so far in Q3 versus 8.7% in Q2. Piper Sandler does not expect July’s pace to hold for the full quarter but acknowledges “upside to our prior estimates” for the second half. U.S. pricing action is expected in Q4 2025, with selective adjustments by package and channel and reduced promotions to offset aluminum costs. The firm models 3.5% pricing growth in Monster’s core segment, noting that previous increases had “benign” elasticity impacts. Piper Sandler has lifted its EPS forecasts to $2.01 for 2025 and $2.47 for 2026, applying a higher multiple, around 30x 2026 estimates, on confidence that Monster can maintain its growth trajectory. Before you buy stock in MNST, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is MNST one of them?

Click Subscribe #Investing #MonsterBeverage #PiperSandler #StockMarket #Finance

Piper Sandler cuts Cadence to Neutral as valuation rises after strong Q2 Investing.com -- Piper Sandler downgraded Cadence Design (NASDAQ:CDNS) Systems to Neutral from Overweight, saying the stock’s recent rally has pushed its valuation above levels supported by current growth expectations. The firm maintained its price target at $350. Shares had jumped about 7% in after-hours trading following better-than-expected second-quarter results. Cadence posted revenue of $1.28 billion, up 20% year-over-year and 2% above consensus, despite disruptions from U.S. export controls in June. Non-GAAP operating margin came in at 42.8%, beating estimates by 100 basis points, while earnings per share were $1.65 versus expectations of $1.56. Growth was broad-based, with core electronic design automation (EDA) revenue rising 16%, system design and analysis up more than 35%, and IP revenue climbing over 25%. The company raised its full-year revenue forecast by $50 million and now expects 12.9% growth for 2025, with operating margins guided to 44% and EPS raised by $0.12. Still, Piper Sandler said Cadence’s stock now trades at roughly 45 times projected 2026 earnings, and 48 times estimated free cash flow, levels that fully reflect the company’s strong performance and outlook. The brokerage said it would need to see a clear improvement in semiconductor market demand to support further upside. Cadence’s backlog stood at $6.4 billion at the end of June, but the figure does not include China due to ongoing export restrictions. The company now expects modest full-year growth in China, up from a flat outlook previously. Before you buy stock in CDNS, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is CDNS one of them?

Click Subscribe #PiperSandler #Cadence #StockMarket #InvestmentNews #Q2Results

Seeking Up to 15% Dividend Yield? Piper Sandler Suggests 2 Dividend Stocks to Buy - TipRanks Seeking Up to 15% Dividend Yield? Piper Sandler Suggests 2 Dividend Stocks to Buy  TipRanks

Click Subscribe #DividendStocks #Investing #StockMarket #PiperSandler #FinancialNews

UMB Financial stock rating reiterated by Piper Sandler ahead of earnings Investing.com - Piper Sandler maintained its Overweight rating and $135.00 price target on UMB Financial (NASDAQ:UMBF) on Tuesday, citing expectations for strong second-quarter earnings. The research firm projects UMB Financial’s operating earnings per share will exceed consensus estimates by $0.09, driven by core net interest income growth of approximately 13% compared to the previous quarter, which includes a full quarter of HTLF acquisition results. Piper Sandler attributes this growth to UMB’s "more durable balance sheet growth prospects" through continued market share gains. Piper Sandler forecasts UMB’s core net interest margin will increase by 4 basis points quarter-over-quarter to 2.79%, benefiting from the redeployment of excess liquidity and anticipated funding cost relief. The firm also sees potential for UMB to exceed consensus fee income estimates of $181 million, with Piper Sandler projecting $184 million as UMB increases market share across various verticals and expands its HSA business to HTLF’s client base. Operating expenses may come in better than consensus expectations, with Piper Sandler estimating $372 million versus consensus of $375 million, potentially reflecting greater cost savings from the HTLF acquisition, which has a 27.5% target. Credit quality is expected to improve following elevated net charge-offs in the first quarter, which reached 45 basis points primarily due to HTLF integration, while legacy UMB’s net charge-offs were only 10 basis points. Piper Sandler believes UMB Financial is well-positioned to regain its historical price-to-earnings premium of 2-3 times, compared to its current 8.9x multiple on Piper Sandler’s 2026 earnings estimate, while peers trade at 9.2x. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #StockMarket #Finance #Investing #Earnings #PiperSandler

Amgen stock maintains Overweight rating at Piper Sandler despite GI data Investing.com - Piper Sandler has reiterated an Overweight rating and $328.00 price target on Amgen (NASDAQ:AMGN) following the company’s release of detailed MariTide tolerability data. The market reacted negatively to the obesity drug’s gastrointestinal tolerability profile, particularly the incidence of nausea and vomiting, which at first glance appeared more problematic than competing options. This reaction led to Amgen shares losing approximately $10 billion in market value. Piper Sandler’s analysis indicates that one- and two-step dose escalation strategies showed clear improvements in the drug’s tolerability profile, consistent with management’s statements when top-line results were announced in December. The research firm believes that the even lower starting doses and three-step dose escalation regimens incorporated into the pivotal studies should produce a more commercially acceptable nausea and vomiting profile for the weight loss medication. Piper Sandler maintains its positive outlook on MariTide, noting that the drug demonstrates commercially competitive weight loss efficacy and improvements in cardiometabolic parameters despite the market’s concerns about the tolerability data. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?

Click Subscribe #Amgen #StockMarket #Investing #PiperSandler #OverweightRating

Click Subscribe #SkywardSpecialty #InsuranceStocks #PiperSandler #StockMarket #InvestmentNews

Piper Sandler: Is Tesla the only U.S. automaker with a plan to bypass China? Investing.com -- Tesla appears to be the only U.S. automaker seriously pursuing battery independence from China, according to Piper Sandler. “Thanks to vertical integration, Tesla (NASDAQ:TSLA) is the only car company that is trying to source batteries, at scale, without relying on China,” the firm said in a note following a call with battery expert Jordan Giesige. For its in-house 4680 batteries, “China reliance is already approaching 0%,” Piper Sandler noted. While full independence remains years away, the firm emphasized that “at least Tesla has a plan.” The company is reportedly working to refine its own lithium, produce cathode active materials (CAM), coat its own electrodes, and assemble batteries entirely in-house. “No other U.S. entity can make similar claims,” argues Piper Sandler. One major focus is Tesla’s dry battery electrode (DBE) process, which Piper Sandler said “is 5x–6x faster than coating anodes or cathodes with a wet process.” If scalable, they believe it could deliver “material” capital and operating cost savings. The process may start scaling by year-end, though Piper said Giesige highlighted that this remains uncertain. Tesla is also making progress on domestic iron-based (LFP) battery production. Piper Sandler said Giesige pointed out that the company is likely trying to commission “~10GWh of domestic LFP capacity,” which could eventually cover 25% of the 40GWh required for Megapack production in the U.S. Ultimately, even if Tesla’s novel refining methods fail, the firm argues that the company wouldn’t be disadvantaged relative to competitors, because no one else is trying. “Success isn’t assured, and in the next 2+ years, there’s no way to insulate the U.S. supply chain from China... but at least Tesla has a plan,” concluded Piper Sandler.

Click Subscribe #Tesla #BatteryIndependence #EVs #AutomotiveIndustry #PiperSandler

Piper Sandler downgrades Expedia as Q1 results show weak B2C trends Investing.com -- Piper Sandler on Thursday downgraded Expedia (NASDAQ:EXPE) shares to Underweight from Neutral and slashed its price target to $135 from $174 following the travel technology company’s latest earnings report. The company’s shares plummeted nearly 10% in premarket trading Friday as investors reacted to the print. The brokerage described Expedia’s first-quarter results as “mixed,” highlighting the 1% miss in bookings and revenues, while EBITDA was better than anticipated. The company’s bookings for the first quarter amounted to $31.4 billion, a modest year-over-year growth of 4%, which is a slowdown from the 13% growth observed in the previous quarter. The business-to-consumer (B2C) segment was noted as the primary factor for this deceleration, with consumer business growing only 1% year-over-year compared to 9% in the fourth quarter. In contrast, the business-to-business (B2B) segment showed resilience with 14% growth, helped by geographic and product diversity. Revenue for the quarter was reported at $3 billion, up 3% year-over-year but 1% below Street forecasts. Meanwhile, EBITDA of $296 million exceeded the street’s expectation of $270 million. Piper Sandler voiced concerns regarding weaker consumer demand and a decline in U.S. inbound travel, with inbound travel to the U.S. down by 7% and travel from Canada falling 30%. Among Expedia’s properties, Hotels.com faced pressure due to its international mix and foreign exchange factors, while Vrbo bookings remained positive, growing in line with the market. “Brand Expedia remained the strongest,” analysts Thomas Champion and James Callahan noted. Looking ahead, management’s guidance for the second quarter anticipates bookings and revenue growth of 2-4% and 3-5% year-over-year, respectively. However, forecasts for fiscal year 2025 now call for bookings growth of 2-4%, a drop from the previously projected 4-6%, and revenue growth of 3-5%, down from the earlier 4-6% estimate. On a positive note, EBITDA margins are expected to expand by 75-100 basis points, an improvement from the prior estimate of 50 basis points, partly due to recent headcount reductions. “Comments suggest that full-year guidance extrapolates the trends in April through the balance of the year,” analysts said. “We hope that’s the case, but the compares get steadily more challenging with 2024 B2C growth acceleration from -3% in 1Q24 to 1%, 4%, and 9% through the balance of the year,” they added. “Lower government spend doesn’t help, nor does the possibility of a weakening U.S. consumer.” Piper Sandler’s updated thesis reflects concerns over the top-line performance and the vulnerability of Expedia’s stock due to its heavy concentration in the U.S. market, which could be affected by a potential decline in travel demand. Should you invest $2,000 in EXPE right now? ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is EXPE one of them?

Click Subscribe #Expedia #PiperSandler #Investing #StockMarket #FinancialNews

Piper Sandler starts Adidas at Overweight on attractive risk-return profile Investing.com -- Piper Sandler on Monday began coverage on Adidas (ETR:ADSGN) (OTC:ADDYY) shares with an Overweight rating and a €265 price target, voicing confidence in the company’s earnings growth trajectory and highlighting limited exposure to trade-related risks. The brokerage sees attractive risk-reward in Adidas shares, supported by solid sales and earnings momentum heading into 2025. Piper Sandler analysts note that the stock trades at 9x EV/EBITDA and 19x price-to-earnings (P/E) on 2026 estimates, while expecting average earnings per share (EPS) growth of around 50% over the next two years. They also point to Adidas’s broad but shallow product lineup as a strategic advantage that helps the company navigate changing consumer preferences. Piper Sandler highlights North America as a key area for both market share and margin improvement. The region accounts for 22% of Adidas’s total sales but contributes just 11% to operating income, with EBIT margins still well below 2021 levels despite recent gains. The brokerage firm estimates that Adidas holds a 13% share of the North American athletic footwear market in 2024, down about 400 basis points compared to 2019. It models low double-digit growth in the region for both 2025 and 2026, which would imply a recovery to 15% market share by 2026. “Our sensitivity analysis suggests for each 1-point gain in North America share, Adidas sees ~15 bps of EBIT margin expansion and ~€0.35 in EPS,” analysts led by Anna Andreeva said. The sportswear giant’s goal of a 10% operating margin by 2026 was also underlined, based on gross margins (GM) of 50–52% and disciplined cost controls. “At 50.8%, Adidas’s GM are ~100 bps above recent averages but 200 bps below ‘18/’19 and should have upside as the company drives full price business/Apparel share further,” the analysts continued. Despite a 13% year-to-date share price decline, the analysts see the stock’s valuation as attractive, especially with YEEZY-related headwinds now in the past and strong momentum across both Lifestyle and Performance categories. “Adi’s broad portfolio gives downside support,” the report said, pointing to the growing popularity of new running models like the Adizero EVO SL as older Terrace franchises mature. Piper Sandler expects sales of €25.9 billion and EPS of €7.10 in 2025, followed by €28.5 billion in revenue and €10.50 in EPS in 2026. The €265 target implies a multiple of ~25x 2026 EPS, which Piper views as a modest premium to peers but justified given Adidas’s earnings trajectory.

Click Subscribe #Adidas #Investing #StockMarket #Finance #PiperSandler

Piper starts on Roku, Trade Desk; sees connected TV strength and near term risks Investing.com -- Piper Sandler assumed coverage of Roku (NASDAQ:ROKU) and The Trade Desk (NASDAQ:TTD) with Neutral ratings on both stocks, highlighting strong positions in connected TV (CTV) but taking a cautious stance amid mixed ad market signals and macro risks. For Roku, Piper set a $65 price target, noting the company’s leadership in CTV, consistent financial outperformance, and growing viewership share. We see much to like with Roku, analysts wrote, citing an 82% year-over-year rise in Roku Channel viewing hours and an eight-quarter streak of beats on revenue and gross profit. However, Piper remains on the sidelines for now, citing concerns over ad market volatility, tariffs, and losses in Roku’s devices and smart home segments. “We’re sidelined but are looking for an open jump shot,” the note said. On The Trade Desk, Piper also initiated with a Neutral rating and $55 target. The firm noted TTD’s strategic positioning in CTV and retail media, and its strong technology partnerships. But a disappointing Q4 earnings miss and what Piper called an “opportunistic reset” in guidance temper the near-term view. “We worry this could take 1–2 more quarters to realign,” the analysts wrote. While both companies benefit from the secular shift from linear to digital TV, Piper said it is waiting for cleaner entry points, citing mixed monthly ad buyer data and ongoing macro uncertainty. Should you invest $2,000 in TTD right now? ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is TTD one of them?

Click Subscribe #PiperSandler #Roku #TradeDesk #ConnectedTV #Streaming

Piper Sandler clips Tesla price target, expects Q1 print to be a ’non-event’ TSLA hereremove ads Latest comments Install Our AppScan QR code to install app Google Play App Store Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #Tesla #PiperSandler #StockMarket #Investing #Finance

Thryv Therapeutics is excited to join the 2025 Piper Sandler Virtual Cardio Day on April 1! Our leadership team will sit for a fireside chat at 11:30 a.m. ET, sharing insights on SGK1 inhibition for LQTS, HF & AFib.

📢 Read more: thryvtrx.com/news/piper-s...

#PiperSandler #SGK1 #BioTech

Piper Sandler on Tesla: Concerns over brand damage may be overstated Piper Sandler believes fears about Tesla's brand taking a major hit are exaggerated. While Elon Musk’s political behaviour may have slightly affected demand, the larger issue behind Tesla's sharp drop in first-quarter deliveries was supply-side—specifically factory shutdowns that limited Model Y production. The firm notes demand remains strong, and with new products and a robo-taxi launch on the horizon, it maintains an Overweight rating and a $450 price target for the stock. --- Piper Sandler is an US investment bank/financial services firm, This article was written by Eamonn Sheridan at www.forexlive.com.

| ctrendfx.com | bit.ly/CTrendFX1 #Tesla #ElonMusk #PiperSandler #InvestmentBank #FinancialServices

iPhone: re indiscusso tra gli adolescenti USA
#Adolescenti #Aggiornamento #AI #Android #Apple #AppleIntelligence #IntelligenzaArtificiale #iOS18 #iPhone #MercatoSmartphone #Notizie #PiperSandler #Smartphone #Sondaggio #StatiUniti #Tecnologia #USA
www.ceotech.it/iphone-re-in...